Why is Bafna Pharma. falling/rising?

As of 24-Jun, Bafna Pharmaceuticals Ltd is experiencing a price increase, currently at 76.93, reflecting a change of 2.43 or 3.26% upward. The stock has outperformed its sector today by 3.05%, although it has shown a decline in investor participation, with delivery volume dropping significantly by 99.18% against the 5-day average. In terms of returns, the stock has increased by 1.25% over the past week and 3.07% over the past month, while it has underperformed year-to-date with a decline of 2.50%. Positive factors contributing to the stock's recent movement include a strong ability to service debt, healthy long-term growth in net sales and operating profit, and attractive valuation metrics, despite a recent drop in profits of 14.2%. However, the company faces challenges with poor management efficiency indicated by a low ROCE of 8.63% and a reduction in promoter confidence, as they have decreased their stake by 13.3% in the previous quarter.
In the broader market context, Bafna Pharmaceuticals has outperformed the Sensex over the past week and month, with the benchmark index only increasing by 0.77% in both periods. However, the stock has underperformed year-to-date and over the last year compared to the Sensex, which has risen by 5.92% and 6.40%, respectively. This indicates that while the stock is currently rising, it still faces significant challenges in maintaining momentum against broader market trends and investor sentiment, particularly given the declining promoter confidence and low profitability metrics.